Compass Pathways Plc shares climbed 3.5% in pre-open trading to $14.10, extending a recovery from its 52-week low of $3.24 as investors positioned for the COMP006 Phase 3 26-week durability data release. Management had guided that this readout would arrive in early Q3 2026 - a window the company is now in - and the market treats the result as the final major clinical data point before Compass’ planned New Drug Application (NDA) submission for COMP360 in treatment-resistant depression, targeted for Q4 2026.
Market confidence has been reinforced by recent analyst actions. Canaccord boosted its price target to $20 from $18 in late June while keeping a Buy rating, and H.C. Wainwright reiterated a Buy recommendation around the same time. Across 15 analysts covering the company, the consensus rating is "Strong Buy," with a 12-month average price target of $22.33.
Regulatory developments have also played a role in sentiment. The Food and Drug Administration has granted Compass a rolling NDA review for COMP360 and awarded a Commissioner’s National Priority Voucher for the candidate, a mechanism that can shorten the post-filing review period by one to two months. Additionally, a White House executive order directing the Drug Enforcement Administration to accelerate rescheduling reviews for psychedelics that have completed Phase 3 trials has added momentum across the sector.
The broader market provided a mixed backdrop for Compass’ move. The Dow Jones Industrial Average posted a fresh record, rising by more than 1%, while the NASDAQ declined as investors rotated away from growth and technology names. A U.S. jobs report published this morning contributed to an uncertain macro tone. Market observers note that Compass’ pre-market advance appears rooted in its own clinical and regulatory narrative rather than a general market uplift.
Taken together, the approaching COMP006 data readout, positive analyst sentiment and a regulatory environment that is relatively constructive for psychedelic medicines have supported buying interest in the stock. At $14.10 pre-market, the shares remain within reach of their 52-week high of $15.40.
What to watch next
- Timing and content of the COMP006 26-week durability readout, which is viewed as the pivotal late-stage data point before an intended Q4 2026 NDA filing for COMP360.
- Any updates related to the rolling NDA review process and the potential impact of the Commissioner’s National Priority Voucher on review timing.
- Sector-level responses to the White House directive on DEA rescheduling reviews for psychedelics with completed Phase 3 trials.